---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-314755"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2022-12-29T23:59:59+00:00"
generated_at: "2026-06-20T21:48:26.019105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bluebird bio closes sale of rare pediatric disease PRV to argenx for $102M

## Summary
- Completed sale of Rare Pediatric Disease Priority Review Voucher to argenx BV for $102M cash.
- PRV awarded under FDA program for SKYSONA approval for cerebral adrenoleukodystrophy.
- Transaction closed on Dec 29, 2022 after HSR waiting period expiration.
- Terms consistent with previously disclosed Asset Purchase Agreement from Nov 29, 2022.

## SEC filing metadata
- accession: 0001193125-22-314755
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2022-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/0001193125-22-314755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/d413031d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-314755
- JSON: https://secwatch.observer/filing/0001193125-22-314755.json
- Plain text: https://secwatch.observer/filing/0001193125-22-314755.txt

## Key facts
- M&A Transactions
  bluebird bio, Inc. completed a disposition involving argenx BV for $102.0 million in cash (closed 2022-12-29).
  - Action: disposition
  - Counterparty: argenx BV
  - Consideration: $102.0 million in cash
  - Closing: 2022-12-29
  source text: Report on Form 8-K filed with the Securities and Exchange Commission on November 30, 2022 (the “Prior 8-K”). Pursuant to the PRV Transfer Agreement, Buyer paid the Company $102.0 million in cash upon the closing of the Asset Sale. The foregoing description of the material terms of the PRV Transfer Agreement does not purport to be complete and is qualified in its
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000119312522314755/0001193125-22-314755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.